Table 3. Outcome Events at 5 Years in RAMP-HT Participants and Usual Care Patients.
| Event | RAMP-HT participants (n = 108 045) | Usual care patients (n = 104 662) | ARR, % | HRa | P value | NNT | ||
|---|---|---|---|---|---|---|---|---|
| Cases with event, No. (%) | Incidence rate (cases/100 person years) (95% CI) | Cases with event, No. (%) | Incidence rate (cases/100 person-years) (95% CI) | |||||
| All outcome event | 12 784 (11.8) | 3.1 (3.0-3.1) | 27 514 (26.3) | 5.4 (5.3-5.5) | 14.5 | 0.58 (0.57-0.59) | <.001 | 11 (10-11) |
| CVD | 9167 (8.5) | 2.1 (2.1-2.2) | 17 261 (16.5) | 3.4 (3.3-3.4) | 8.0 | 0.62 (0.61-0.64) | <.001 | 16 (15-16) |
| CHD | 3964 (3.7) | 0.9 (0.8-0.9) | 6607 (6.3) | 1.3 (1.2-1.3) | 2.6 | 0.66 (0.63-0.69) | <.001 | 47 (44-51) |
| Heart failure | 1799 (1.7) | 0.4 (0.4-0.5) | 5094 (4.9) | 0.9 (0.9-0.9) | 3.2 | 0.54 (0.51-0.58) | <.001 | 49 (46-52) |
| Stroke | 4378 (4.1) | 1.0 (1.0-1.0) | 8467 (8.1) | 1.6 (1.5-1.6) | 4.0 | 0.64 (0.61-0.66) | <.001 | 36 (33-38) |
| ESKD | 808 (0.7) | 0.2 (0.2-0.2) | 2409 (2.3) | 0.4 (0.4-0.4) | 1.6 | 0.54 (0.50-0.59) | <.001 | 106 (97-120) |
| Diabetes | 10235 (9.5 | 2.4 (2.4-2.5) | 14 724 (14.1) | 3.1 (3.1-3.2) | 4.6 | 0.83 (0.80-0.85) | <.001 | 41 (36-48) |
| All-cause mortality | 4833 (4.5) | 1.2 (1.2-1.3) | 15 144 (14.5) | 2.8 (2.7-2.8) | 10.0 | 0.52 (0.50-0.54) | <.001 | 17 (16-18) |
| CVD mortality | 1532 (1.4) | 0.4 (0.4-0.4) | 576 (5.3) | 1.0 (1.0-1.1) | 3.9 | 0.51 (0.48-0.54) | <.001 | 43 (40-46) |
| Non-CVD mortality | 3301 (3.1) | 0.8 (0.8-0.8) | 9568 (9.1) | 1.8 (1.7-1.8) | 6.0 | 0.54 (0.51-0.56) | <.001 | 45 (43-48) |
Abbreviations: ARR, absolute risk reduction; CHD, coronary heart disease; CVD, cardiovascular disease; ESKD, end-stage kidney disease; HR, hazard ratio; NNT, number needed to treat; RAMP-HT, Risk Assessment and Management Program for Hypertension.
a
Hazard ratios were adjusted by gender, age, smoking status, systolic blood pressure, diastolic blood pressure, fasting glucose, low-density lipoprotein cholesterol, TC/HDL-C ratio, triglyceride, body mass index, estimated glomerular filtration rate, Charlson Comorbidity Index and the usages of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other antihypertensive drugs, statin and fibrate at baseline.